Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Abide Therapeutics Inc.
Headquarters: San Diego, CA, United States of America
Website: N/A
Year Founded: 2011
Status: Acquired
BioCentury | Mar 17, 2025
Product Development
Lundbeck’s next chapter: from psychiatry to rare neuro
Leaving past limitations behind, Danish pharma widens its technology aperture to brain shuttles, AI and more
BioCentury | May 22, 2024
Management Tracks
FDA vet Singh joining CRDO Precision for Medicine
Plus: de Moerlooze to depart Bavarian and updates from Engitix, Actio and Oruka
BioCentury | Oct 18, 2022
Product Development
Lundbeck pivot emphasizes first in class in revamped pipeline
Dunsire era brings new blood to R&D, appetite for risk, and open doors for partnering
BioCentury | Jun 25, 2019
Finance
Frontier aims for previously unreachable ‘hot spot’ targets with $67M series A
VCs led by MPM, Deerfield and Droia believe Frontier can reach previously undruggable targets through chemoproteomics
BioCentury | May 6, 2019
Company News
Lundbeck’s $250M Abide takeout lands Tourette compound, discovery hub
BioCentury | Mar 22, 2019
Targets & Mechanisms
Deconvoluting translation at Scripps
Why Scripps Research's non-profit model is doubling down on target discovery
BioCentury | Nov 7, 2018
Translation in Brief
M is for Chemoproteomic Momentum
Why methionine could have a place in the chemoproteomics toolbox
Items per page:
1 - 10 of 32